ES2554927T3 - Formulación que comprende un derivado de fenilaminopirimidina como agente activo - Google Patents

Formulación que comprende un derivado de fenilaminopirimidina como agente activo Download PDF

Info

Publication number
ES2554927T3
ES2554927T3 ES11764851.9T ES11764851T ES2554927T3 ES 2554927 T3 ES2554927 T3 ES 2554927T3 ES 11764851 T ES11764851 T ES 11764851T ES 2554927 T3 ES2554927 T3 ES 2554927T3
Authority
ES
Spain
Prior art keywords
weight
pharmaceutical composition
relation
total weight
nrc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11764851.9T
Other languages
English (en)
Spanish (es)
Inventor
Durga Maheswari Parvataneni
Siddhartha YEDLURI
Venkata Satyanarayana APPADWEDULA
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2554927(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Application granted granted Critical
Publication of ES2554927T3 publication Critical patent/ES2554927T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES11764851.9T 2011-03-07 2011-08-10 Formulación que comprende un derivado de fenilaminopirimidina como agente activo Active ES2554927T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
GB201103860 2011-03-07
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (1)

Publication Number Publication Date
ES2554927T3 true ES2554927T3 (es) 2015-12-28

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11764851.9T Active ES2554927T3 (es) 2011-03-07 2011-08-10 Formulación que comprende un derivado de fenilaminopirimidina como agente activo

Country Status (33)

Country Link
US (1) US9895367B2 (enExample)
EP (1) EP2683381B1 (enExample)
JP (1) JP5788534B2 (enExample)
KR (1) KR101767296B1 (enExample)
CN (1) CN103561742B (enExample)
AP (1) AP4076A (enExample)
AU (1) AU2011361921B2 (enExample)
BR (1) BR112013022930A2 (enExample)
CA (1) CA2829015C (enExample)
CO (1) CO6811851A2 (enExample)
CY (1) CY1116968T1 (enExample)
DK (1) DK2683381T3 (enExample)
EA (1) EA024610B1 (enExample)
ES (1) ES2554927T3 (enExample)
GB (1) GB2488788B (enExample)
GE (1) GEP20156410B (enExample)
HR (1) HRP20151382T1 (enExample)
HU (1) HUE025562T2 (enExample)
IL (1) IL228218A (enExample)
MA (1) MA35088B1 (enExample)
MX (1) MX339130B (enExample)
MY (1) MY158693A (enExample)
NZ (1) NZ614903A (enExample)
PH (1) PH12013501844A1 (enExample)
PL (1) PL2683381T3 (enExample)
PT (1) PT2683381E (enExample)
RS (1) RS54420B1 (enExample)
SG (1) SG193349A1 (enExample)
SI (1) SI2683381T1 (enExample)
SM (1) SMT201500235B (enExample)
UA (1) UA111074C2 (enExample)
WO (1) WO2012120328A1 (enExample)
ZA (1) ZA201306643B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6896738B2 (ja) 2015-12-18 2021-06-30 ナトコ ファーマ リミテッド フェニルアミノピリミジン誘導体を含む医薬組成物
WO2017115316A1 (en) * 2015-12-29 2017-07-06 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
RS65257B1 (sr) 2018-03-14 2024-03-29 Kandy Therapeutics Ltd Nova farmaceutska formulacija koja sadrži dvojne antagoniste receptora nk-1/nk-3
CN113473974A (zh) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
KR100509776B1 (ko) * 1997-07-29 2005-08-24 파마시아 앤드 업존 캄파니 엘엘씨 친지성 화합물의 자가유화 제제
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
HRP20070146B1 (hr) * 2004-09-09 2015-12-04 Natco Pharma Limited Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze
US20080207904A1 (en) * 2006-10-26 2008-08-28 Macdonald Peter Imatinib base, and imatinib mesylate and processes for preparation thereof
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
EP2073850B1 (en) * 2007-04-30 2010-10-27 Intezyne Technologies Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
KR20100126464A (ko) * 2008-03-04 2010-12-01 낫코 파마 리미티드 페닐아미노 피리미딘 유도체의 결정 형태
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
JP5791500B2 (ja) * 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤

Also Published As

Publication number Publication date
IL228218A (en) 2016-06-30
CN103561742A (zh) 2014-02-05
ZA201306643B (en) 2014-11-26
DK2683381T3 (en) 2015-12-21
GB2488788A (en) 2012-09-12
SI2683381T1 (sl) 2016-01-29
AP2013007128A0 (en) 2013-09-30
BR112013022930A2 (pt) 2016-12-06
EA201391280A1 (ru) 2014-02-28
NZ614903A (en) 2014-08-29
CY1116968T1 (el) 2017-04-05
WO2012120328A1 (en) 2012-09-13
JP2014507463A (ja) 2014-03-27
PL2683381T3 (pl) 2016-06-30
RS54420B1 (sr) 2016-04-28
MA35088B1 (fr) 2014-05-02
AP4076A (en) 2017-03-23
GEP20156410B (en) 2015-12-10
KR101767296B1 (ko) 2017-08-10
PH12013501844A1 (en) 2015-10-23
SMT201500235B (it) 2015-10-30
MX339130B (es) 2016-05-13
KR20140016926A (ko) 2014-02-10
AU2011361921A1 (en) 2013-09-26
SG193349A1 (en) 2013-10-30
MX2013010160A (es) 2013-12-06
HRP20151382T1 (hr) 2016-02-12
US20130338180A1 (en) 2013-12-19
GB201103860D0 (en) 2011-04-20
EA024610B1 (ru) 2016-10-31
CO6811851A2 (es) 2013-12-16
US9895367B2 (en) 2018-02-20
MY158693A (en) 2016-11-15
CA2829015A1 (en) 2012-09-13
GB2488788B (en) 2013-07-10
JP5788534B2 (ja) 2015-09-30
UA111074C2 (uk) 2016-03-25
EP2683381B1 (en) 2015-09-16
AU2011361921B2 (en) 2016-06-09
AU2011361921A2 (en) 2014-10-30
EP2683381A1 (en) 2014-01-15
PT2683381E (pt) 2015-11-02
HUE025562T2 (en) 2016-03-29
CA2829015C (en) 2018-01-02
CN103561742B (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
ES2554927T3 (es) Formulación que comprende un derivado de fenilaminopirimidina como agente activo
EP2616053B1 (en) Pharmaceutical compositions of curcumin
RU2009131749A (ru) Многофазные фармацевтические композиции плохо растворимых в воде лекарственных соединений для уменьшения вариабельности при приеме после еды/натощак и для улучшения пероральной биодоступности
AU2015270187A1 (en) Oral pharmaceutical composition of isotretinoin
JP2020105183A (ja) 低水溶性薬剤の低融解イオン性塩の組成物および調製方法
ES2643135T3 (es) Composiciones farmacéuticas que comprenden alisporivir
TW202320735A (zh) 卡博替尼的自微乳組合物
US20200345646A1 (en) Liquid filled formulations of pde5 inhibitors
ES2358205T3 (es) Composición farmacéutica para administración oral.
KR100986531B1 (ko) 액상의 아세클로페낙을 함유하는 캡슐제
JP2000355552A (ja) オキサトミド製剤